Skip to main content
. Author manuscript; available in PMC: 2024 Jun 1.
Published in final edited form as: Leukemia. 2023 Apr 19;37(6):1194–1203. doi: 10.1038/s41375-023-01900-5

Table 2.

Estimated PD parameters of dasatinib and ponatinib in orally-dosed mice

Dasatinib Ponatinib
Emax (ng/ml) (CV%) 7.3 (67%) 2.6 (56%)
EC50 (ng/ml) (CV%) 32.0 (69%) 50.2 (47%)
EC90 (ng/ml) (CV%) 33.0 (14%) 63.0 (13%)
Maximum pLCK inhibition (%) (CV%) 88.0 (8%) 72.0 (16%)
Median duration of pLCK/LCK <50% (hrs/day) (10th-90th percentile) 20 mg/kg 10.0 (4.7, 19.7) 15 mg/kg 10.5 (0, 24.0)
40 mg/kg 15.5 (8.9, 24.0) 30 mg/kg 14.8 (0, 24.0)

PD, pharmacodynamic.